

Wei Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1862871/publications.pdf>

Version: 2024-02-01

38
papers

2,257
citations

394421

19
h-index

302126

39
g-index

42
all docs

42
docs citations

42
times ranked

3317
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer mutation profiles predict ICIs efficacy in patients with non-small cell lung cancer. <i>Expert Reviews in Molecular Medicine</i> , 2022, 24, e16.	3.9	1
2	Tumour-associated macrophages heterogeneity drives resistance to clinical therapy. <i>Expert Reviews in Molecular Medicine</i> , 2022, 24, e17.	3.9	12
3	Prognostic values, ceRNA network, and immune regulation function of SDPR in KRAS-mutant lung cancer. <i>Cancer Cell International</i> , 2021, 21, 49.	4.1	5
4	Reduced PHLPP Expression Leads to EGFR-TKI Resistance in Lung Cancer by Activating PI3K-AKT and MAPK-ERK Dual Signaling. <i>Frontiers in Oncology</i> , 2021, 11, 665045.	2.8	7
5	Targeted therapies for RET-fusion cancer: Dilemmas and breakthrough. <i>Biomedicine and Pharmacotherapy</i> , 2020, 132, 110901.	5.6	2
6	Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. <i>Nature Communications</i> , 2020, 11, 4607.	12.8	69
7	Dual inhibition of VEGF and PARP suppresses KRAS-mutant colorectal cancer. <i>Neoplasia</i> , 2020, 22, 365-375.	5.3	7
8	Impact of molecular subtypes on metastatic behavior and overall survival in patients with metastatic breast cancer: A single center study combined with a large cohort study based on the Surveillance, Epidemiology and End Results database. <i>Oncology Letters</i> , 2020, 20, 1-1.	1.8	15
9	EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression. <i>Molecular Cancer</i> , 2019, 18, 165.	19.2	160
10	Inhibition of NF B improves sensitivity to irradiation and EGFR TKIs and decreases irradiation induced lung toxicity. <i>International Journal of Cancer</i> , 2019, 144, 200-209.	5.1	13
11	<i>MET</i> Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of <i>EGFR</i>-mutant Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 506-515.	4.1	52
12	High PHLPP1 expression levels predicts longer time of acquired resistance to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 59000-59007.	1.8	6
13	Hypoxia-Responsive Mir-301a and Mir-301b Promote Radioresistance of Prostate Cancer Cells via Downregulating NDRG2. <i>Medical Science Monitor</i> , 2016, 22, 2126-2132.	1.1	52
14	Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type <i>EGFR</i>. <i>Oncotarget</i> , 2016, 7, 16273-16281.	1.8	9
15	Abnormal amphiregulin expression correlates with gastric cancer prognosis. <i>Oncotarget</i> , 2016, 7, 76684-76692.	1.8	14
16	Therapeutic activity of glycoengineered anti GM</sc>2 antibodies against malignant pleural mesothelioma. <i>Cancer Science</i> , 2015, 106, 102-107.	3.9	9
17	Mir-20a Induces Cell Radioresistance by Activating the PTEN/PI3K/Akt Signaling Pathway in Hepatocellular Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 1132-1140.	0.8	95
18	Dual PI3K/mTOR Inhibitors, GSK2126458 and PKI-587, Suppress Tumor Progression and Increase Radiosensitivity in Nasopharyngeal Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 429-439.	4.1	63

#	ARTICLE	IF	CITATIONS
19	MiR-200c inhibits autophagy and enhances radiosensitivity in breast cancer cells by targeting UBQLN1. <i>International Journal of Cancer</i> , 2015, 136, 1003-1012.	5.1	107
20	Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma. <i>Tumor Biology</i> , 2015, 36, 7375-7384.	1.8	5
21	MET inhibitor PHA-665752 suppresses the hepatocyte growth factor-induced cell proliferation and radioresistance in nasopharyngeal carcinoma cells. <i>Biochemical and Biophysical Research Communications</i> , 2014, 449, 49-54.	2.1	14
22	Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor-Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 1663-1671.	7.0	81
23	Dual Inhibition of Met Kinase and Angiogenesis to Overcome HGF-Induced EGFR-TKI Resistance in EGFR Mutant Lung Cancer. <i>American Journal of Pathology</i> , 2012, 181, 1034-1043.	3.8	55
24	Pleural Mesothelioma Instigates Tumor-Associated Fibroblasts To Promote Progression via a Malignant Cytokine Network. <i>American Journal of Pathology</i> , 2011, 179, 1483-1493.	3.8	54
25	Antiangiogenic therapies for malignant pleural mesothelioma. <i>Frontiers in Bioscience - Landmark</i> , 2011, 16, 740.	3.0	6
26	Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2-expressing small cell lung cancer cells. <i>Cancer Science</i> , 2011, 102, 2157-2163.	3.9	31
27	Periostin: a putative mediator involved in tumour resistance to anti-angiogenic therapy?. <i>Cell Biology International</i> , 2011, 35, 1085-1088.	3.0	9
28	The EGFR Ligands Amphiregulin and Heparin-Binding EGF-like Growth Factor Promote Peritoneal Carcinomatosis in CXCR4-Expressing Gastric Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 3619-3630.	7.0	46
29	E7080 Suppresses Hematogenous Multiple Organ Metastases of Lung Cancer Cells with Nonmutated Epidermal Growth Factor Receptor. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1218-1228.	4.1	14
30	Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 2260-2269.	7.0	101
31	HGF-MET in Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer. <i>Current Signal Transduction Therapy</i> , 2011, 6, 228-233.	0.5	2
32	Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 174-183.	7.0	93
33	Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>Clinical Cancer Research</i> , 2009, 15, 6630-6638.	7.0	255
34	HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 967-976.	4.2	57
35	E7080, a Multi-Tyrosine Kinase Inhibitor, Suppresses the Progression of Malignant Pleural Mesothelioma with Different Proangiogenic Cytokine Production Profiles. <i>Clinical Cancer Research</i> , 2009, 15, 7229-7237.	7.0	55
36	Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells. <i>Lung Cancer</i> , 2009, 63, 23-31.	2.0	17

#	ARTICLE	IF	CITATIONS
37	Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations. <i>Cancer Research</i> , 2008, 68, 9479-9487.	0.9	574
38	The Therapeutic Efficacy of Anti-Vascular Endothelial Growth Factor Antibody, Bevacizumab, and Pemetrexed against Orthotopically Implanted Human Pleural Mesothelioma Cells in Severe Combined Immunodeficient Mice. <i>Clinical Cancer Research</i> , 2007, 13, 5918-5925.	7.0	69